Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), participated virtually via videoconference on Thursday in the opening session of the First USP Africa Regional Annual Conference, which focused on supporting pharmaceutical manufacturing across the African continent.
The conference serves as a strategic platform for discussing pharmaceutical initiatives in Africa, facilitating the exchange of scientific and regulatory perspectives, and promoting local pharmaceutical manufacturing through regulatory harmonization and enhanced collaboration among stakeholders. It also aims to strengthen synergies between the activities of the United States Pharmacopeia (USP) and regional regulatory initiatives, with particular emphasis on combating the circulation of substandard and falsified medical products within African markets.
During the meeting, Dr. El-Ghamrawy delivered a presentation reaffirming the Egyptian Drug Authority's support for the United States Pharmacopeia as an internationally recognized compendium that establishes quality standards for
medicines and contributes to safeguarding patient safety through the promotion of the rational use of medicines and the safe utilization of pharmaceutical products.
The Chairman of the Egyptian Drug Authority expressed his appreciation for the conference, describing it as one of the most significant annual events at the continental level. He reaffirmed the Authority's commitment to close collaboration and the effective implementation of the standards and scientific principles embodied in the United States Pharmacopeia. He also highlighted the exemplary cooperation between the USP and other international organizations as a model for fostering global regulatory convergence.
Dr. El-Ghamrawy emphasized that these efforts are aligned with the Authority's broader strategy to achieve shared objectives through cooperation with international partners and the adoption of internationally recognized standards in the field of pharmaceutical regulation. Such efforts contribute to strengthening both regulatory performance and the pharmaceutical industry in Egypt, while supporting the development of a more resilient and sustainable healthcare ecosystem.
The Egyptian Drug Authority remains committed to promoting regulatory excellence and fostering international partnerships aimed at enhancing the quality, safety, and efficacy of medical products, thereby reinforcing Egypt's position as a leading regional and international hub for pharmaceutical regulation and manufacturing.